Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01790308

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01790308
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01790308. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
CSII
Intervention (Drug)
Liraglutide
Lead sponsor
Sun Yat-sen University (class: other)

Record details

Record id
cardio:ct-nct01790308
Content hash
91ea1a505bf701a809e48b7110683085818bf3636bc21357aa1d27fc806f77cf